AI-powered drug discovery startup Peptris has successfully raised ₹70 Cr ($7.7 Mn) in a recent Series A funding round. This funding, co-led by IAN Alpha Fund and Speciale Invest, aims to scale Peptris’s AI-driven platform, accelerating the preclinical drug discovery process.
Founded in 2019, Peptris focuses on leveraging AI and machine learning to streamline the drug discovery phase. By integrating unsupervised learning and generative AI, the company aims to design optimized molecules suitable for drug applications.
The new capital will be used to advance Peptris’s pipeline, move programs towards clinical readiness, and establish global partnerships. The startup plans to launch multiple Novel Chemical Entities (NCE) programs and explore drug repurposing initiatives that could potentially revive shelved clinical-stage drugs.
Peptris also intends to expand its operations, including growing its team across functions such as biology, chemistry, data science, and AI. The company will establish dedicated business development units in the US and Europe.
Peptris’s revenue model primarily relies on licensing deals, milestone payments, and royalties. The startup collaborates with academia, biotech, pharma companies, and rare disease organizations to drive its AI-driven drug discovery efforts.
Source: Inc42 Media